Amphotericin B-induced Nephrogenic Diabetes Insipidus in a Case of Cryptococcemia

Line
Title: Amphotericin B-induced Nephrogenic Diabetes Insipidus in a Case of Cryptococcemia
Authors: Fujita, Yukio; Kasahara, Kei; Uno, Kenji; Konishi, Mitsuru; Maeda, Koichi; Yoshimoto, Eiichiro; Murakawa, Koichi; Mikasa, Keiichi; Amano, Itsuto; Morii, Takeshi; Kimura, Hiroshi
Publisher: Internal Medicine
Date Published: March 01, 2005
Reference Number: 691
Line
A 66-year-old woman with malignant lymphoma became neutropenic during chemotherapy and developed cryptococcemia. After amphotericin B had been commenced, she developed significant hypokalemia and polyuria, though her renal function remained stable. The laboratory findings showed no evidence of renal tubular acidosis. With vigorous water and potassium replacement, amphotericin B had been continued until the cumulative dose reached 2.5 g. After the cessation of amphotericin B, the hypokalemia and polyuria resolved promptly. Based on theses findings, she was diagnosed as nephrogenic diabetes insipidus with hypokalemia and without renal tubular acidosis due to amphotericin B. This complication is usually reversible, and vigorous water and potassium replacement may allow completion of treatment by amphotericin B, though careful monitoring of body water balance and renal function is of importance.
The publisher has not granted permission to reproduce this article on our website. You may, however, read this article at the Internal Medicine website. In order to view this document, you will need Acrobat Reader. If you do not already have Acrobat Reader or need to upgrade, click here.
To return to this page, use your "back" key.

This translation by the NDI Foundation is to assist the lay reader. To provide a clear, accessible interpretation of the original article, we eliminated or simplified some technical detail and complicated scientific language. We concentrated our translation on those aspects of the article dealing directly with NDI. The NDI Foundation thanks the researchers for their work toward understanding and more effectively treating this disorder.
© Copyright NDI Foundation 2007 (JC)

Fujita, et al, report on a 66-year-old woman with malignant lymphoma cancer who developed a type of fungal infection called cryptococcemia while being treated in the hospital for her cancer. In response, the medical team treated her with amphotericin B, a widely used antifungal agent. Shortly after the woman began receiving amphotericin B, she showed low levels of potassium in her blood and her urine volume increased markedly. Though rare, NDI can develop in response to amphotericin B, and this is what happened to this woman. Since her condition was severe, and the infection made it more so, the team continued to treat her with amphotericin B. However, they made sure to replace the water and potassium lost due to the resultant NDI. When the team ceased amphotericin B therapy, the woman’s blood potassium levels and urine output returned to normal.

It remains unknown as to how amphotericin B induces NDI. Amphotericin B-induced NDI may express itself in different ways. That is, the NDI symptoms in the body may result from several distinct physiological malfunctions in response to the drug, depending on the patient. However, in general, amphotericin B-induced NDI is usually reversible when the drug stops being administered. Treating physicians can still consider it as an option if the infectious disease they are treating is severe, but the treatment should stop if the lowered potassium blood levels and lack of body water balance can not be countered during the course of the treatment.